Insulet Corporation ($PODD) Stock Forecast: Up 5.1% Today

What is Insulet Corporation?

Insulet Corporation (PODD) is a medical technology company recognized for its Omnipod insulin delivery systems. The company is actively engaged in fostering innovation and enhancing its global presence within the diabetes care market.

Why is Insulet Corporation going up?

PODD stock is up 5.1% on Jun 26, 2026 16:46

• Insulet Corporation's stock (PODD) demonstrated a notable bullish trend today.
• The appointment of Jonathan "Jay" Mazelsky, former CEO of another company, to Insulet's Board of Directors signifies a strategic emphasis on operational excellence and creating value for long-term shareholders.
• With Mazelsky's track record in driving growth and share prices at his previous company, there is anticipation that he will assist Insulet in leveraging its innovations and international expansion, likely contributing to investor optimism and the positive market movement.
• The company's robust revenue growth fueled by its Omnipod 5 system, along with projections for future growth despite potential risks, may have further bolstered investor confidence and propelled the stock price upwards.

PODD Price Chart

PODD Technical Analysis

PODD News

Price to sales forward of Insulet Corporation – BMV:PODD

This article provides financial information for Insulet Corporation (BMV:PODD), specifically its price to sales forward metric. The data is available on TradingView, which sources its market and reference data from ICE Data Services and FactSet, respectively. The article itself is a minimal financial data point without further analysis.

https://www.tradingview.com/symbols/BMV-PODD/financials-statistics-and-ratios/price-sales-fwd/

If You Invested $1000 in Insulet 10 Years Ago, This Is How Much You'd Have Now

An investment of $1000 in Insulet (PODD) ten years ago would now be worth $5,389.63, a gain of 438.96%. The article highlights Insulet's business, focusing on its Omnipod insulin delivery systems and discusses analyst expectations for future upside despite potential risks. This performance significantly outpaced the S&P 500 and gold over the same period.

https://finance.yahoo.com/markets/stocks/articles/invested-1000-insulet-10-years-123004697.html

Insulet's New Board Director: A Bet on Execution Over Market Hype

Insulet Corporation has appointed Jonathan “Jay” Mazelsky to its Board of Directors, signaling a strategic focus on operational execution and long-term shareholder value. Despite strong revenue growth driven by its Omnipod 5 system, Insulet's stock has lagged, making Mazelsky's proven track record of boosting revenue and stock prices at IDEXX Laboratories particularly relevant. His expertise in scaling medical technology companies and navigating competitive markets is expected to help Insulet capitalize on its innovation and expand globally.

https://briefglance.com/articles/insulets-new-board-director-a-bet-on-execution-over-market-hype

Insulet Announces Appointment of Jonathan J. Mazelsky to its Board of Directors

Insulet Corporation announced the appointment of Jonathan ("Jay") Mazelsky to its Board of Directors, effective July 1, 2026, as an independent director. Mazelsky, former President and CEO of IDEXX Laboratories, is recognized for his strong leadership in translating science into solutions and driving growth, which Insulet believes will be integral to expanding access and strengthening the Omnipod brand. He expressed his honor to join the board, citing Insulet's category-leading business and commitment to reducing the burden of diabetes.

https://www.biospace.com/press-releases/insulet-announces-appointment-of-jonathan-j-mazelsky-to-its-board-of-directors

Insulet Appoints Former IDEXX CEO Jay Mazelsky to Board of Directors

Insulet Corporation has appointed Jonathan "Jay" Mazelsky, former CEO of IDEXX Laboratories, to its Board of Directors, effective July 1, 2026. Mazelsky's extensive experience in global medical technology and diagnostics is expected to help Insulet expand its Omnipod insulin delivery systems and strengthen its leadership in diabetes care. His appointment reflects Insulet's ongoing strategy to grow its presence in the diabetes technology market and explore new therapeutic applications for its wearable Pod platform.

https://www.citybiz.co/article/865816/insulet-appoints-former-idexx-ceo-jay-mazelsky-to-board-of-directors/

Trending Today

Insulet Corporation Price History

10.05.2026 - PODD Stock was down 5.0%

• Insulet Corp's stock faced bearish pressure, which could be attributed to profit-taking following recent increases, despite the company's robust fundamentals and insider purchases showing faith in its performance.
• While the stock has been outperforming competitors and the market, a notable decline from its 52-week peak may have led to some selling activity.
• The purchase of company shares by Insulet's Independent Chair, Timothy Christian, might indicate enduring confidence in the company's growth prospects, potentially offsetting short-term pessimism.
• Today's downturn in Insulet Corp's stock could be influenced by profit-taking, market dynamics, and investor response to recent insider transactions, despite the company's strong market position and growth trajectory.

26.05.2026 - PODD Stock was up 5.1%

• Today's positive movement in Insulet's stock (PODD) could be linked to the market's favorable reaction to the appointment of Jonathan "Jay" Mazelsky to its Board of Directors.
• Mazelsky's successful track record in enhancing revenue and stock prices at IDEXX Laboratories, combined with his proficiency in growing medical technology firms, may have instilled confidence in investors regarding Insulet's future growth potential.
• Investors likely perceive Mazelsky's appointment as a strategic decision by Insulet to prioritize operational performance and enhance long-term shareholder value, indicating a potential shift towards improved financial outcomes and market positioning.
• The market's enthusiasm surrounding Mazelsky's appointment may have overshadowed concerns about Insulet's past stock performance, contributing to today's positive movement in the company's stock.

26.05.2026 - PODD Stock was up 5.1%

• Insulet Corporation's stock (PODD) demonstrated a notable bullish trend today.
• The appointment of Jonathan "Jay" Mazelsky, former CEO of another company, to Insulet's Board of Directors signifies a strategic emphasis on operational excellence and creating value for long-term shareholders.
• With Mazelsky's track record in driving growth and share prices at his previous company, there is anticipation that he will assist Insulet in leveraging its innovations and international expansion, likely contributing to investor optimism and the positive market movement.
• The company's robust revenue growth fueled by its Omnipod 5 system, along with projections for future growth despite potential risks, may have further bolstered investor confidence and propelled the stock price upwards.

27.04.2026 - PODD Stock was down 6.0%

• The recall of approximately 7 million Omnipod insulin pods due to a manufacturing defect causing insulin leakage has led to a loss of investor confidence in Insulet Corporation.
• The voluntary medical device correction announcement, along with the expected costs of up to $50 million in 2026, has raised concerns about the company's financial performance and operational efficiency.
• The identified cause of the manufacturing issue, the implementation of corrective actions, and the provision of free replacements show Insulet's commitment to product quality and customer safety, but the market reaction remains negative due to the potential impact on sales and reputation.

27.04.2026 - PODD Stock was down 6.0%

• Insulet Corporation's stock plummeted to a 52-week low of $143.95, marking a challenging year with a 52.46% decline. The significant drop is linked to a voluntary recall of about 7 million Omnipod insulin pods due to a manufacturing defect. This has raised concerns among investors about product safety and future sales.
• The recall of 7 million patch pumps in the Omnipod product line due to a manufacturing defect leading to insulin leakage and potential medication under-delivery has sparked worries about the company's quality control processes and financial implications, with anticipated costs of up to $50 million this year.
• Despite maintaining a Buy rating, analysts at BTIG have slashed the price target for Insulet Corporation from $260 to $235, indicating revised near-term expectations for the Omnipod product line. This shift has contributed to investor concerns and a reassessment of the company's prospects in the competitive medical device sector.
• The negative outlook for medical device firms is further highlighted by Boston Scientific's stock decline of 6% following a reduction in its full-year guidance. This demonstrates the challenges facing the industry and the broader impact on market performance in the sector.

27.04.2026 - PODD Stock was down 7.4%

• The downturn in Insulet Corporation's stock (PODD) is linked to a recall of around 7 million Omnipod insulin pods due to a manufacturing flaw causing insulin leakage, raising concerns about product quality and impact on sales and revenue.
• Boston Scientific’s stock decline by over 6% post a reduction in full-year organic growth guidance potentially influenced negative investor sentiment in the healthcare sector, triggering a wider sell-off affecting companies like Insulet Corporation.
• Despite Insulet Corporation's efforts in rectifying the manufacturing issue through a voluntary correction, the projected costs of up to $50 million in 2026 and the subsequent impact on adjusted results likely pressured the stock price further.
• Ongoing industry uncertainties, exemplified by challenges faced by Boston Scientific and Insulet Corporation, are contributing factors to the bearish trend observed in Insulet Corporation's stock (PODD) today.

09.05.2026 - PODD Stock was up 5.2%

• Insulet Corp. (PODD) exhibited bearish movements as it underperformed its competitors, resulting in a lower closing price despite the overall market trending positively.
• This decline could be linked to investors taking profits following the recent consecutive increases in stock value, prompting a sell-off.
• To boost investor confidence and push the stock price upwards, the company may need to showcase more robust growth prospects or release positive developments in the future.

05.05.2026 - PODD Stock was up 5.4%

• Strong insider confidence, with notable purchases by the Independent Chair and CEO at higher prices, may have fueled the bullish movement in PODD stock today, signaling optimism regarding the company's future.
• The recent improvements in Insulet's Omnipod 5 Automated Insulin Delivery System post FDA clearance likely played a role in the positive market sentiment, demonstrating the company's dedication to advancing their products.
• Despite a recent voluntary medical device correction for certain Omnipod insulin pods, the overall upbeat attitude stemming from insider transactions and product upgrades appears to have overshadowed any apprehensions, driving the bullish trend in PODD stock today.

11.05.2026 - PODD Stock was down 6.8%

• The bearish movement in Insulet Corp (PODD) stock today is linked to various factors:
• Despite positive clinical data on the Omnipod 6 system for type 2 diabetes, the stock lagged behind its rivals and the broader market, resulting in a 5.58% decline.
• A 5.3% surge in shares may suggest robust fundamentals and undervaluation; however, the stock showed an overall negative performance for the day.
• The stock's price fluctuations and volatility could be impacted by market sentiment, investor confidence, and potential worries regarding product concentration and quality concerns.
• In summary, the mixed performance of Insulet Corp (PODD) stock today highlights the company's continuous endeavors to enhance its automated insulin delivery systems, alongside the challenges of maintaining market competitiveness and investor confidence.

02.05.2026 - PODD Stock was down 5.1%

• The overturning of the $59.4 million trade secret verdict against rival EOFlow could have created uncertainty among investors, leading to a sell-off of Insulet's stock.
• The decline in Insulet's stock price target from $379 to $294 by TD Cowen, along with other analyst actions, might have contributed to the bearish movement as investors reevaluate their positions.
• The lack of success in CareDx's appeal for a $45 million false advertising award against Natera Inc. could have impacted market sentiment towards medical device companies like Insulet.
• Despite the overall bearish movement, it's worth noting that Insulet had outperformed the broader market in the past few trading sessions, indicating potential volatility in response to industry-specific news.

04.05.2026 - PODD Stock was up 5.8%

• The bullish movement in Insulet's stock (PODD) can be attributed to multiple positive developments within the company:
• New data and innovations for the Omnipod brand were announced at a key industry event, displaying improved clinical outcomes and streamlined diabetes management.
• A significant purchase of 3,450 shares by director Elizabeth H. Weatherman at an average price of $144.20 per share demonstrated confidence in the company's future prospects.
• Mike Panos has been appointed as Chief Commercial Officer, leveraging extensive experience in the medtech sector to propel growth for Insulet's Omnipod platform.
• Enhancements for the Omnipod 5 Automated Insulin Delivery System were launched, incorporating personalized health tech features and expanded sensor compatibility to strengthen Insulet's position in the competitive diabetes technology market. These advancements likely influenced the bullish movement in Insulet's stock.

14.04.2026 - PODD Stock was down 5.5%

• Insulet Corporation's stock hit a 52-week low and dropped 6.7% due to nine analyst downgrades and price target cuts, reflecting a fundamental reassessment of the company's near-term prospects.
• Despite strong Q1 financial results, concerns about guidance and valuation led to a significant decline in the stock price.
• The coordinated action of analyst firms, including Barclays maintaining an Underweight rating, suggests potential uncertainties regarding Insulet's competitive dynamics or guidance revisions.
• Benchmark initiating coverage and a 3.4% rise in shares amid a challenging year-to-date performance indicate ongoing interest in Insulet's user-friendly solutions for diabetes management, despite today's bearish market movement.